Trial Profile
A Phase 1-2 Study of Sirolimus, Docetaxel and Carboplatin for Treatment of Patients With Metastatic, Castration Resistant Prostate Cancer: (Rapamycin Inhibition of DDSP [RID])
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 05 Oct 2021
Price :
$35
*
At a glance
- Drugs Carboplatin (Primary) ; Docetaxel (Primary) ; Sirolimus (Primary)
- Indications Carcinoma; Prostate cancer
- Focus Adverse reactions; Pharmacodynamics; Pharmacogenomic
- 20 Jul 2020 According to Clinicaltrials.gov the study was stopped because due to insufficient funding
- 14 Jul 2020 Status changed from active, no longer recruiting to discontinued.
- 10 Apr 2020 Planned End Date changed from 1 Feb 2021 to 1 Feb 2023.